Cardio Diagnostics Holdings, Inc.

CDIOW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Operating Activities
Net Income $-6.5M $-8.4M $-8.4M $-4.7M $-620.4K
Depreciation & Amortization $65.2K $19.7K $19.2K $16.0K $16.0K
Depreciation $160.1K $113.8K $3.8K $0
Amortization $5.3K $16.0K $16.0K $16.0K
Stock-Based Compensation $110.2K $2.6M $1.3M $0 $60.0K
Net Cash from Operating Activities $-5.7M $-5.0M $-5.7M $-5.1M $-585.3K
Investing Activities
Capital Expenditures $187.3K $214.8K $575.7K
Business Acquisitions
Net Cash from Investing Activities $-419.3K $-404.2K $-794.3K $-368.0K $-364.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $3.4M $11.9M $3.6M $9.1M $1.2M
Net Change in Cash
Free Cash Flow $-5.9M $-5.2M $-6.2M